|
Variable
| |
Total population
| | |
Females
| | |
Males
| |
|---|
|
HR
|
95%CI
|
p-value
|
HR
|
95%CI
|
p-value
|
HR
|
95%CI
|
p-value
|
|---|
|
Age
|
1.18
|
1.11–1.26
|
< 0.0001
|
1.17
|
1.05–1.31
|
0.005
|
1.22
|
1.12–1.32
|
< 0.0001
|
|
IHD
|
1.33
|
0.79–2.24
|
0.29
|
1.85
|
0.70–4.88
|
0.21
|
0.93
|
0.48–1.82
|
0.84
|
|
Hypertension
|
1.26
|
0.74–2.16
|
0.40
|
2.10
|
0.75–5.86
|
0.16
|
1.23
|
0.66–2.29
|
0.52
|
|
Diabetes
|
1.21
|
0.76–1.92
|
0.41
|
2.06
|
0.90–4.73
|
0.09
|
0.84
|
0.48–1.48
|
0.55
|
|
AECI/ARB
|
1.03
|
0.63–1.70
|
0.91
|
0.65
|
0.26–1.63
|
0.36
|
1.29
|
0.70–2.38
|
0.41
|
|
Beta blockers
|
0.75
|
0.46–1.24
|
0.26
|
0.61
|
0.27–1.42
|
0.25
|
0.73
|
0.38–1.39
|
0.33
|
|
Atrial fibr.
|
2.02
|
1.11–3.66
|
0.02
|
4.72
|
1.60–13.92
|
0.005
|
1.83
|
0.91–3.67
|
0.09
|
|
Hb < 120 g/L
|
1.55
|
0.86–2.79
|
0.14
|
3.70
|
1.52–9.00
|
0.004
|
1.10
|
0.48–2.54
|
0.82
|
|
EF < 40%
|
1.77
|
0.93–3.37
|
0.08
|
3.12
|
0.82–11.85
|
0.09
|
1.62
|
0.72–3.66
|
0.24
|
|
TSP-1 rs2228262, A/A
|
1.48
|
0.80–2.75
|
0.21
|
7.12
|
1.11–45.78
|
0.04
|
1.14
|
0.59–2.23
|
0.69
|
- ACEI angiotensin convering enzyme inhibitors, ARB angiotensin receptor inhibitors, EF ejection fraction, HR hazard ratio
